Y-26763
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H530442

CAS#: 127408-31-5

Description: Y-26763 is Kir6 (KATP) channel opener and active metabolite of Y-27152. Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels. Y-26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of KATP channels. Y-26763 activated K(ATP) channels in a reversible manner with a similar activity to diazoxide. Y-26763-induced inhibition of insulin release is dependent upon the activation of K(ATP) channels in human beta-cells.

Chemical Structure

img
Y-26763
CAS# 127408-31-5
Instruction

Theoretical Analysis

Hodoodo Cat#: H530442
Name: Y-26763
CAS#: 127408-31-5
Chemical Formula: C14H16N2O4
Exact Mass: 276.11
Molecular Weight: 276.292
Elemental Analysis: C, 60.86; H, 5.84; N, 10.14; O, 23.16

Price and Availability

Size Price Availability Quantity
10mg USD 550 2 Weeks
50mg USD 1450 2 Weeks
Bulk inquiry

Synonym: Y-26763; Y 26763; Y26763.

IUPAC/Chemical Name: N-[(3S,4R)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-hydroxyacetamide

InChi Key: IWTCFIIOUXJOOV-OLZOCXBDSA-N

InChi Code: InChI=1S/C14H16N2O4/c1-8(17)16(19)12-10-6-9(7-15)4-5-11(10)20-14(2,3)13(12)18/h4-6,12-13,18-19H,1-3H3/t12-,13+/m1/s1

SMILES Code: CC(N([C@H]1[C@H](O)C(C)(C)OC2=CC=C(C#N)C=C12)O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 276.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cosgrove KE, Straub SG, Barnes PD, Chapman J, Sharp GW, Dunne MJ. Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9. PubMed PMID: 14975702.

2: Okada H, Kobayashi S, Ikeda T. [Protection afforded by a novel K channel opener (Y-26763), against glycerol-induced acute renal failure (ARF) in rats]. Nihon Jinzo Gakkai Shi. 1997 Jul;39(5):464-9. Japanese. PubMed PMID: 9283211.

3: Fukunari A, Miyai H, Shinagawa K, Kawahara K, Nakajima T. Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels. Eur J Pharmacol. 1997 Apr 4;323(2-3):197-204. PubMed PMID: 9128839.

4: Rahman F, Kato A, Kawahara K, Nakajima T. Y-26763 protects the working rat myocardium from ischemia/reperfusion injury through opening of KATP channels. Eur J Pharmacol. 1996 Dec 19;317(2-3):293-9. PubMed PMID: 8997613.

5: Hashitani H, Suzuki H, Kumazawa J. Effects of Y-26763, a novel K-channel opener, on electrical responses of smooth muscles in the guinea pig bladder. J Urol. 1996 Apr;155(4):1454-8. PubMed PMID: 8632610.

6: Itoh T, Ito S, Shafiq J, Suzuki H. Effects of a newly synthesized K+ channel opener, Y-26763, on noradrenaline-induced Ca2+ mobilization in smooth muscle of the rabbit mesenteric artery. Br J Pharmacol. 1994 Jan;111(1):165-72. PubMed PMID: 8012692; PubMed Central PMCID: PMC1910042.

7: Kitayama J, Kitazono T, Ooboshi H, Takada J, Fujishima M, Ibayashi S. Long-term effects of benidipine on cerebral vasoreactivity in hypertensive rats. Eur J Pharmacol. 2002 Mar 8;438(3):153-8. PubMed PMID: 11909606.

8: Miyata S, Shibata O, Saito M, Tsuda A, Shibata S, Makita T, Sumikawa K. Effects of ATP-sensitive potassium channel openers on the contractile and phosphatidylinositol responses of the rat trachea. J Anesth. 2002;16(4):279-83. PubMed PMID: 14517619.

9: Kitayama J, Kitazono T, Ooboshi H, Ago T, Ohgami T, Fujishima M, Ibayashi S. Chronic administration of a tyrosine kinase inhibitor restores functional and morphological changes of the basilar artery during chronic hypertension. J Hypertens. 2002 Nov;20(11):2205-11. PubMed PMID: 12409959.

10: Takaba H, Nagao T, Yao H, Kitazono T, Ibayashi S, Fujishima M. An ATP-sensitive potassium channel activator reduces infarct volume in focal cerebral ischemia in rats. Am J Physiol. 1997 Aug;273(2 Pt 2):R583-6. PubMed PMID: 9277542.

11: Fujita H, Takizawa S, Nanri K, Matsushima K, Ogawa S, Shinohara Y. Potassium channel opener reduces extracellular glutamate concentration in rat focal cerebral ischemia. Brain Res Bull. 1997;43(4):365-8. PubMed PMID: 9241438.

12: Takaba H, Nagao T, Ibayashi S, Kitazono T, Fujii K, Fujishima M. Altered cerebrovascular response to a potassium channel opener in hypertensive rats. Hypertension. 1996 Jul;28(1):143-6. PubMed PMID: 8675255.

13: Watanabe Y, Suzuki A, Suzuki H, Itoh T. Effect of membrane hyperpolarization induced by a K+ channel opener on histamine-induced Ca2+ mobilization in rabbit arterial smooth muscle. Br J Pharmacol. 1996 Mar;117(6):1302-8. PubMed PMID: 8882629; PubMed Central PMCID: PMC1909770.

14: Doi K, Nagao T, Kawakubo K, Ibayashi S, Aoyagi K, Yano Y, Yamamoto C, Kanamoto K, Iida M, Sadoshima S, Fujishima M. Calcitonin gene-related peptide affords gastric mucosal protection by activating potassium channel in Wistar rat. Gastroenterology. 1998 Jan;114(1):71-6. PubMed PMID: 9428220.

15: Toyoda K, Fujii K, Takata Y, Ibayashi S, Kitazono T, Nagao T, Fujikawa M, Fujishima M. Age-related changes in response of brain stem vessels to opening of ATP-sensitive potassium channels. Stroke. 1997 Jan;28(1):171-5. PubMed PMID: 8996507.

16: Houjou S, Iizuka K, Dobashi K, Nakazawa T. Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea. Eur Respir J. 1996 Oct;9(10):2050-6. PubMed PMID: 8902466.

17: Kondo M, Tsutsumi T, Mashima S. Potassium channel openers antagonize the effects of class III antiarrhythmic agents in canine Purkinje fiber action potentials. Implications for prevention of proarrhythmia induced by class III agents. Jpn Heart J. 1999 Sep;40(5):609-19. PubMed PMID: 10888381.

18: Sakuta H, Okamoto K. Inhibition by imidazoline and imidazolidine derivatives of glibenclamide-sensitive K+ currents in Xenopus oocytes. Eur J Pharmacol. 1994 Jul 11;259(3):223-31. PubMed PMID: 7982448.

19: Sakuta H, Okamoto K. Effects of Ca2+ channel antagonists and their isomers on glibenclamide-sensitive K+ currents in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Apr 1;255(1-3):1-7. PubMed PMID: 8026535.

20: Yoneda I, Sakuta H, Okamoto K, Watanabe Y. Effects of local anesthetics and related drugs on endogenous glibenclamide-sensitive K+ channels in Xenopus oocytes. Eur J Pharmacol. 1993 Nov 15;247(3):267-72. PubMed PMID: 8307100.